Avidity-Based Capture of PD-L1-Expressing Exosomes via Dendrimer-Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response.

ABSTRACT: A major challenge in immunotherapy is the inability to reliably predict patient responses due to the lack of robust biomarkers. Programmed cell death-ligand 1 (PD-L1)-expressing exosomes represent a promising biomarker candidate; however, existing detection platforms lack the sensitivity and specificity required for clinical translation. It is hypothesized that an avidity-based capture strategy utilizing dendrimer-mediated multivalent binding will effectively enhance molecular avidity and improve the selective capture of PD-L1-expressing exosomes. Supporting this hypothesis, atomic force microscopy (AFM) revealed that dendrimer-peptide conjugates synthesized using generation 7 poly(amidoamine) dendrimers (G7-pPDL1) exhibited ≈2.48-fold higher binding avidity than conventional anti-PD-L1 an

SUBMITTER: Lee J 

PROVIDER: S-EPMC12622428 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature